Literature DB >> 22488585

Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma.

Daniela Capello1, Annunziata Gloghini, Gianluca Baldanzi, Maurizio Martini, Clara Deambrogi, Marco Lucioni, Daniela Piranda, Rosella Famà, Andrea Graziani, Michele Spina, Umberto Tirelli, Marco Paulli, Luigi Maria Larocca, Gianluca Gaidano, Antonino Carbone, Fabiola Sinigaglia.   

Abstract

We investigated immunodeficiency-related non-Hodgkin lymphoma for the presence of molecular alterations affecting negative regulators of the Janus family protein tyrosine kinase/signal transducer and activator of transcription pathway. Protein tyrosine phosphatase, non-receptor type 6/Src homology 2-containing tyrosine phosphatase-1 epigenetic silencing was recurrent in primary effusion lymphoma (100%), and diffuse large B-cell lymphoma (63%), with a higher prevalence in the non-germinal centre subtype, and was associated with the activation of the Janus family protein tyrosine kinase/signal transducer and activator of transcription 3 pathway. Suppressor of cytokine signalling (SOCS)1 and SOCS3 epigenetic silencing were occasionally detected, whereas SOCS1 was frequently mutated in diffuse large B-cell lymphoma and polymorphic post-transplant lymphoproliferative disorders, possibly as a cause of aberrant somatic hypermutation. However, the mutation profile of the coding region of the gene was different from that expected from the aberrant somatic hypermutation process, suggesting that, at least in some cases, SOCS1 mutations may have been selected for their functional activity.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22488585     DOI: 10.1002/hon.2010

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  5 in total

1.  SOCS1 mutation subtypes predict divergent outcomes in diffuse large B-Cell lymphoma (DLBCL) patients.

Authors:  Birgit Schif; Jochen K Lennerz; Christian W Kohler; Stefan Bentink; Markus Kreuz; Ingo Melzner; Olga Ritz; Lorenz Trümper; Markus Loeffler; Rainer Spang; Peter Möller
Journal:  Oncotarget       Date:  2013-01

Review 2.  The role of suppressors of cytokine signalling in human neoplasms.

Authors:  Walid Sasi; Anup K Sharma; Kefah Mokbel
Journal:  Mol Biol Int       Date:  2014-03-16

3.  Curcumin Regulates Anti-Inflammatory Responses by JAK/STAT/SOCS Signaling Pathway in BV-2 Microglial Cells.

Authors:  Chiara Porro; Antonia Cianciulli; Teresa Trotta; Dario Domenico Lofrumento; Maria Antonietta Panaro
Journal:  Biology (Basel)       Date:  2019-06-27

4.  Critical analysis of the potential for targeting STAT3 in human malignancy.

Authors:  Noah D Peyser; Jennifer R Grandis
Journal:  Onco Targets Ther       Date:  2013-07-30       Impact factor: 4.147

5.  Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.

Authors:  Rebecca J Leeman-Neill; Craig R Soderquist; Francesca Montanari; Patricia Raciti; David Park; Dejan Radeski; Mahesh M Mansukhani; Vundavalli V Murty; Susan Hsiao; Bachir Alobeid; Govind Bhagat
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 9.941

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.